Clinical Analysis of Gene Mutation in Adult Patients with B-ALL and Its Influence on Clinical Prognosis.
10.19746/j.cnki.issn.1009-2137.2020.06.013
- Author:
Mei DENG
1
;
Wen-Li ZUO
1
;
Chun-Lei ZHANG
1
;
Xu-Dong WEI
1
;
Xiao-Yu LI
2
Author Information
1. Department of Hematology, Tumor Hospital of Henan Province,Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China.
2. Department of Hematology, Central Hospital of Zhengzhou, Zhengzhou 450000, Henan Province, China E-mail: dm20070530@163.com.
- Publication Type:Journal Article
- MeSH:
Adult;
Humans;
Mutation;
Patients;
Prognosis;
Proportional Hazards Models;
Retrospective Studies
- From:
Journal of Experimental Hematology
2020;28(6):1867-1872
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the gene mutation in adult patients with B-ALL and its influence on clinical prognosis.
METHODS:Clinical data of 226 adult patients with B-ALL were retrospectively analyzed in the period from August 2011 to February 2018. The incidence of gene mutation in all patients were detected, and the influence of mutation gene on clinical prognosis were estimated. Cox regression model were used to evaluate the independent prognostic factors.
RESULTS:208 (92.04%) of 226 patients showed gene mutations, and the median mutation number was 2 (0-8). Among them, 54 cases (23.89%) showed 14 or more mutations. The top five mutation types of all patients were SF1, FAT1, MPL, PTPNII and N-RAS respectively. The median OS and median RFS times of 226 patients were 27.0 (5.5-84.0) months and 22.5 (0-81.0) months respectively. The OS and RFS times of Ph
CONCLUSION:Gene mutations are common in all adult B-ALL patients, and the clinical prognosis of patients with JAK and epigenetics-related signaling pathway mutations is worsen, while the WBC level closely relates to the clinical prognosis of the patients.
